BACKGROUND: Human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated not only with some severe manifestations, such as HTLV-1-associated myelopathy (HAM) and ATLL, but also with other, less severe conditions. Some studies have reported neurologic manifestations that did not meet all the criteria for the diagnosis of HAM in individuals infected with HTLV-1; these conditions may later progress to HAM or constitute an intermediate clinical form, between asymptomatic HTLV-1 carriers and those with full myelopathy. This study evaluated the prognostic value and looked for a possible association of those parameters with the intermediate syndrome (IS) status and HAM status. METHODS: Proviral load (PVL), spontaneous lymphoproliferation, interferon (IFN)-γ spontaneous production was quantified in samples of asymptomatic and HAM patients, as well as patients with IS. RESULTS: The critical age range was 50-60 years for IS outcome and more of 60 years for HAM outcome, with an increased risk of 2.5-fold for IS and 6.8-fold for HAM. IFN-γ was increased in patients with IS compared with asymptomatic carriers (ACs) (p = 0.007) and in patients with HAM compared with ACs (p = 0.03). Lymphoproliferation was increased in patients with HAM vs ACs (p = 0.0001) and patients with IS (p = 0.0001). PVL was similar between groups. CONCLUSION: IFN-γ has high specificity of prediction of subject remain asymptomatic compared with PVL and lymphoproliferation assay tests. IFN-γ has been shown to be a biomarker of progression to intermediate stage and to HAM. The association of other markers with manifestations associated with HTLV-1 infection that does not meet the HAM criteria should be verified.
BACKGROUND: Human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated not only with some severe manifestations, such as HTLV-1-associated myelopathy (HAM) and ATLL, but also with other, less severe conditions. Some studies have reported neurologic manifestations that did not meet all the criteria for the diagnosis of HAM in individuals infected with HTLV-1; these conditions may later progress to HAM or constitute an intermediate clinical form, between asymptomatic HTLV-1 carriers and those with full myelopathy. This study evaluated the prognostic value and looked for a possible association of those parameters with the intermediate syndrome (IS) status and HAM status. METHODS: Proviral load (PVL), spontaneous lymphoproliferation, interferon (IFN)-γ spontaneous production was quantified in samples of asymptomatic and HAM patients, as well as patients with IS. RESULTS: The critical age range was 50-60 years for IS outcome and more of 60 years for HAM outcome, with an increased risk of 2.5-fold for IS and 6.8-fold for HAM. IFN-γ was increased in patients with IS compared with asymptomatic carriers (ACs) (p = 0.007) and in patients with HAM compared with ACs (p = 0.03). Lymphoproliferation was increased in patients with HAM vs ACs (p = 0.0001) and patients with IS (p = 0.0001). PVL was similar between groups. CONCLUSION: IFN-γ has high specificity of prediction of subject remain asymptomatic compared with PVL and lymphoproliferation assay tests. IFN-γ has been shown to be a biomarker of progression to intermediate stage and to HAM. The association of other markers with manifestations associated with HTLV-1 infection that does not meet the HAM criteria should be verified.
Authors: I Kubonishi; T Kubota; T Sawada; Y Tanaka; H Machida; O Yoshida; A Fukushima; H Ueno; Y Ohtsuki; I Miyoshi Journal: Int J Hematol Date: 1997-08 Impact factor: 2.490
Authors: Carlos Fernando Apoliano; Tatiane Assone; Bosco Christiano Maciel da Silva; Marcelo Andreetta Corral; Augusto Cesar Penalva de Oliveira; Luiz Augusto Marcondes Fonseca; Alberto José da Silva Duarte; Yuyang Tang; Jorge Casseb Journal: AIDS Res Hum Retroviruses Date: 2019-10-03 Impact factor: 2.205
Authors: Daniel Gonçalves Chaves; Camila Campos Sales; Poliane de Cássia Gonçalves; Maria Clara Fernandes da Silva-Malta; Luiz Cláudio Romanelli; João Gabriel Ribas; Anna Bárbara de Freitas Carneiro-Proietti; Marina Lobato Martins Journal: J Med Virol Date: 2016-02-03 Impact factor: 2.327
Authors: Mariana Garcia Croda; Augusto César Penalva de Oliveira; Maria Paulina Posada Vergara; Francisco Bonasser; Jerusa Smid; Alberto José da Silva Duarte; Jorge Casseb Journal: J Neurol Sci Date: 2008-02-06 Impact factor: 3.181
Authors: Paula Benencio; Nicolás Ducasa; Lourdes Arruvito; Inés Irurzun; Laura Praino; Magdalena Lamberti; María Beraza; Carolina Berini; Mirna Biglione Journal: Front Med (Lausanne) Date: 2021-11-10